{"id":"W2158202057","doi":"10.1016/s0140-6736(12)61768-1","title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","year":2012,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1193,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital; NeuroRx Research (Canada)","funders":"National Institutes of Health; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"Alemtuzumab; Multiple sclerosis; Medicine; Randomized controlled trial; Disease; Internal medicine; Physical therapy; Oncology; Psychiatry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1151705557353955,"score_gpt":0.3443890657103396,"score_spread":0.2292185099749441,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}